BI 811283 in Various Solid Tumours
The main objective of this trial is to provide safety data in terms of drug-related adverse events (AE) for the recommendation of the dose for further trials in the development of BI 811283.

Secondary objectives are the collection of antitumour efficacy data and the determination of the pharmacokinetic profile of BI 811283.
Neoplasms
DRUG: BI 811283|DRUG: BI 811283|DRUG: BI 811283
Maximum tolerated dose, 3-4 weeks
Safety profile: incidence and intensity of AEs graded according to the common terminology criteria for AEs, incidence of DLT, throughout the study period|Progression free survival (PFS), Objective response, Response duration, Pharmacodynamic analysis, Basic pharmacokinetics, throughout the study period
The main objective of this trial is to provide safety data in terms of drug-related adverse events (AE) for the recommendation of the dose for further trials in the development of BI 811283.

Secondary objectives are the collection of antitumour efficacy data and the determination of the pharmacokinetic profile of BI 811283.